// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Role of the day care unit in the optimal management of heart failure patients

Stuart Rosen - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

The pre-HFpEF entity: a window of opportunity to prevent and halt the progression to HF with preserved ejection fraction (HFpEF)

Patrick Tran - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Left ventricular diastolic dysfunction

N/A

SGLT2 inhibition in heart failure with a reduced ejection fraction: how many patients would benefit?

Jacquelyn Hooper - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Does outpatient based IV diuretic treatment for acute heart failure give patients hope?

Kenneth Wong - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Anticoagulants and antiplatelets in COVID-19: impact on survival and thromboembolism development

Thomas Salmon - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Clopidogrel bisulfate

Side effects of sacubitril/valsartan influence outcomes in heart failure populations: a retrospective study

Sheethal Kumar - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

Sacubitril/valsartan

Women with early onset hypertension are more likely to have cardiac MRI findings associated with future development of heart failure than men

Howell Williams - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Prevalence and adverse cardiac events in anomalous aortic origin of coronary artery (AAOCA) in ct coronary angiography in west of Scotland

Punit Bedi - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Anomalous aortic origin of a coronary artery

N/A

Spect myocardial coronary flow reserve - the initial glasgow experience

Nicholas Goodfield - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Angina

N/A

The role of echocardiography in implantable cardiac electronic device infection

Alice Cowley - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

AS-35

Determining systematic bias in the assessment of left ventricular function between transthoracic echo and cardiac MRI using new generation imaging systems

Sally Chapman - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Left ventricular dysfunction

N/A

Prevalence of echocardiographic abnormalities in patients hospitalised with COVID-19

Dennis Chong - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Systolic dysfunction

N/A

Cardiac magnetic resonance imaging in patients with chest pain, troponin increase and unobstructed coronary arteries; a study of real-world adherence to guidelines from a large UK district general hospital during the COVID-19 pandemic

Oluwaseun Olubodun - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Angina

N/A

CT fractional flow reserve: experiences from a district general hospital

Hazhee Rasoul - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

COVID-19 disease and cardiac involvement – a local experience

Muhammad Raheemuddin Ahmed - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Non-contrast MRI for assessment of thoracic aorta dimension

Mehak Gupta - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

First in vivo pretargeted pet imaging of atherosclerosis with antibodies against forms of modified lipoproteins

Cinzia Marceddu - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

The effect of endurance exercise on right ventricular morphology in female master athletes

Uchenna Ozo - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Logistical demand of running a high-volume MRI service for patients with cardiac implantable electronic devices: findings from a ‘one-stop’ service model

Benjamin Dowsing - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Ct coronary angiography versus ct fractional flow reserve: a single centre experience

MOHANED EGRED - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved